Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
A clinical trial of axitinib plus PF-04856884 or axitinib alone for patients with metastatic renal cancer who have already been treated with an anti-VEGF agent
Part I: To confirm that the combination of PF-04856884 and AG-013736 is safe and tolerable at the doses to be used in Part II of the study. Part II: To document clinical activity of the combination...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer
To assess progression free survival (PFS) of AG-013736 in combination with paclitaxel and carboplatin (Arm A) versus bevacizumab in combination with paclitaxel and carboplatin (Arm B).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma
Phase I To determine the maximum tolerated dose (MTD) and RP2D of PD 0332991 in combination with bortezomib and dexamethasone Phase II To evaluate the anti-tumor activity of PD 0332991 in com...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
A randomized, double-blind phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer
- Compare the Overall Survival (OS) of patients receiving gemcitabine plus AG-013736 versus gemcitabine plus placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
MAJ Il y a 4 ans
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line Regimen
To demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab in prolonging the PFS in the second-line treatment of pa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations